Research programme: H5N1 avian influenza vaccine - Takeda/University of Wisconsin

Drug Profile

Research programme: H5N1 avian influenza vaccine - Takeda/University of Wisconsin

Latest Information Update: 23 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InViragen LLC; University of Wisconsin-Madison
  • Developer Takeda Pharmaceuticals USA; University of Wisconsin-Madison
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 23 Jul 2014 No development reported - Preclinical for Influenza-A virus H5N1 subtype in USA (Intranasal)
  • 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
  • 27 Jan 2011 Preclinical development is ongoing in USA for Influenza-A virus H5N1 subtype
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top